Neuroendocrine Tumor Clinical Trials (April 2026): 533 Recruiting Interventional Studies

Last updated: April 19, 2026

Current Clinical Trial Landscape

Neuroendocrine tumors (NETs) include:

GEP-NETs — gastroenteropancreatic (pancreas, small bowel, stomach)
Carcinoid tumors — lung, GI tract
Pheochromocytoma/paraganglioma

Active research areas in 2026:

PRRT / Lutetium-177 combinations (45 trials)
Somatostatin analogs (39 trials)
Checkpoint inhibitors (176 trials)
mTOR inhibitors (11 trials)

Standard of care: Somatostatin analogs (octreotide, lanreotide) for symptom control. PRRT (Lutathera) for progressive somatostatin receptor-positive tumors. Everolimus or sunitinib for progressive disease.

Recruiting Trials by Treatment Setting

First-Line / Newly Diagnosed

For previously untreated advanced NETs:

Somatostatin analogs: Standard first-line for well-differentiated NETs
- View somatostatin analog trials →
PRRT in first-line:
- NCT06784752 - 177Lu-DOTATATE in Grade 1-2 GEP-NETs

Second-Line / Progressive Disease

After progression on somatostatin analogs:

PRRT:
- NCT05687123 - Lutathera + Sunitinib in pancreatic NETs
- NCT07185672 - PRRT vs PRRT + chemotherapy
Targeted therapy:
- NCT06943755 - Zanzalintinib vs Everolimus

Surgery Combinations

NCT06016855 - Surgical debulking before PRRT

Trials by Treatment Approach

PRRT / Lutetium-177 (45 trials)

Peptide receptor radionuclide therapy targets somatostatin receptors. Lutathera (177Lu-DOTATATE) is approved; trials explore combinations and sequencing. View all →

NCT05687123 - Lutathera + Sunitinib in pancreatic NETs
NCT07185672 - PRRT vs PRRT + chemotherapy (PReCedeNT)
NCT06784752 - 177Lu-DOTATATE in Grade 1-2 GEP-NETs
NCT06016855 - Surgical debulking before PRRT

Somatostatin Analogs (39 trials)

Octreotide and lanreotide control hormone secretion and slow tumor growth. Trials explore higher doses and combinations. View all →

Targeted Therapy (mTOR, TKI)

Everolimus (mTOR inhibitor) and sunitinib (TKI) are approved for progressive NETs. Trials test new agents and combinations.

NCT06943755 - Zanzalintinib vs Everolimus in advanced NETs

View all mTOR/TKI trials →

Immunotherapy (176 trials)

Checkpoint inhibitors show modest activity in NETs; trials explore combinations to improve response. View all →

Trials by NET Subtype

Frequently Asked Questions

How do I find neuroendocrine tumor clinical trials?

Paste your medical summary into ClinTrialFinder to get AI-matched NET trials in minutes. The tool considers your tumor grade, Ki-67 index, primary site, and treatment history.

What neuroendocrine tumor trials are currently recruiting?

There are 533 recruiting interventional trials for neuroendocrine tumors including targeted therapies, PRRT (peptide receptor radionuclide therapy), immunotherapy, and novel agents for GEP-NETs, carcinoid, and pancreatic NETs.

Find NET Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and tumor type.

Find Matching Trials